

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

December 7, 2018
(Date of earliest event reported)

**LABORATORY CORPORATION OF
AMERICA HOLDINGS**

(Exact Name of Registrant as Specified in its Charter)

Delaware

(State or other jurisdiction of Incorporation)

1-11353

(Commission File Number)

13-3757370

(I.R.S. Employer Identification No.)

358 South Main Street,

Burlington, North Carolina

(Address of principal executive offices)

27215

(Zip Code)

336-229-1127

(Registrant's telephone number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure

LabCorp® (NYSE: LH), a leading global life sciences company, announced that its Covance Drug Development business (Covance) has been awarded the 2018 Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award.

Exhibit Index [Exhibit 99.1](#) Press release of the Company, dated December 6, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS
Registrant

By: /s/ EDWARD T. DODSON
Edward T. Dodson
Chief Accounting Officer

December 7, 2018

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact: Sue Maynard (media)

+1 336-436-8263

Media@labcorp.com

Scott Frommer (investors)

+1 336-436-5076

Investor@labcorp.com

Company Information: www.labcorp.com

358 South Main Street
Burlington, NC 27215
Telephone: (336) 584-5171

COVANCE HONORED WITH FROST & SULLIVAN ASIA PACIFIC AWARD FOR FIFTH CONSECUTIVE YEAR

Awarded CRO 2018 Customer Value Leadership Award

Burlington, NC, December 6, 2018 - LabCorp® (NYSE: LH), a leading global life sciences company, today announced that its Covance Drug Development business (Covance) has been awarded the 2018 Frost & Sullivan Asia Pacific CRO Customer Value Leadership Award. The award reflects Covance's continued commitment to its Asia Pacific customers, with investments in deep scientific and therapeutic expertise, and the most comprehensive drug and device development capabilities.

"Our Asia-Pacific organization has transformed in recent years with significant expansion in our operations and new capabilities to meet the unique demands of this exciting market," said John Ratliff, CEO, Covance. "We are honored to work with some of the most innovative companies in the region, who are driving global advances in precision medicine. Whether they need regional services and insight or support with a global strategy, Covance can provide the data-driven solutions and expertise required for success. I'm proud to dedicate this honor to the Asia-Pacific team, who have driven our scientific, technical and operational expansion in the region, while remaining laser-focused on creating value for our customers."

Over two decades, Covance has expanded its Asia-Pacific solutions, including non-clinical development, central laboratory services, clinical development and market access solutions. In 2018, Covance has enhanced its operations in China, India, Korea and Japan and deepened its expertise in key therapeutic areas, including oncology, NASH and cardiovascular outcomes. The recent additions of Chiltern and Sciformix have expanded its footprint in the region, specifically strengthening its clinical development, post-approval and pharmacovigilance offerings.

"With exceptional operational capabilities and wide global reach, Covance is one of the leading CROs globally and in Asia Pacific," said Sanjeev Kumar, industry manager, Transformational Health, Frost & Sullivan. "The company has created a strong brand perception in the minds of customers, resulting in several long-term partnerships and alliances. Consistently providing local and multinational companies with regional knowledge, clinical laboratory testing services, safety and efficacy data for drug development, as well as commercialization solutions, Covance's efforts in addressing customer needs through capacity development is reflected in its strong financial performance. These strategies demonstrate the company's immense potential to continue its impressive progress in the growing Asia-Pacific market."

About LabCorp®

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported net revenues of more than \$10 billion for 2017. To learn more about LabCorp, visit www.LabCorp.com, and to learn more about Covance Drug Development, visit www.Covance.com.

Forward-Looking Statements

This press release contains forward-looking statements including but not limited to statements with respect to estimated 2018 guidance and the related assumptions, the impact of various factors on operating and financial results, expected savings and synergies (including from the LaunchPad initiative and from acquisitions), and the opportunities for future growth. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive

actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, changes in testing guidelines or recommendations, adverse results in material litigation matters, the impact of changes in tax laws and regulations, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, employee relations, and the effect of exchange rate fluctuations. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company's Form 10-K for the year ended December 31, 2017, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company's other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company's filings with the SEC including the information in the Company's Form 10-K for the year ended December 31, 2017, and subsequent Forms 10-Q, under the heading MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

###